BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37820007)

  • 1. Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma.
    Sarin KY; Kincaid J; Sell B; Shahryari J; Duncton MAJ; Morefield E; Sun W; Prieto K; Chavez-Chiang O; de Moran Segura C; Nguyen J; Bronson RT; Plotkin SR; Kochendoerfer GG; Fenn P; Wootton MA; Powala C; de Souza MP; Tsai KY
    Sci Transl Med; 2023 Oct; 15(717):eade1844. PubMed ID: 37820007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
    Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma.
    Wang W; Liu X; Zhang Z; Yin M; Chen X; Zhao S; Wu L
    Oxid Med Cell Longev; 2022; 2022():8172866. PubMed ID: 35965686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032.
    Roh E; Han Y; Reddy K; Zykova TA; Lee MH; Yao K; Bai R; Curiel-Lewandrowski C; Dong Z
    Oncogene; 2020 May; 39(21):4170-4182. PubMed ID: 32277233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.
    Perry J; Ashford B; Thind AS; Gauthier ME; Minaei E; Major G; Iyer NG; Gupta R; Clark J; Ranson M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
    Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.
    Bernat-Peguera A; Navarro-Ventura J; Lorenzo-Sanz L; da Silva-Diz V; Bosio M; Palomero L; Penin RM; Pérez Sidelnikova D; Bermejo JO; Taberna M; Vilariño N; Piulats JM; Mesia R; Viñals JM; González-Suárez E; Capella-Gutierrez S; Villanueva A; Viñals F; Muñoz P
    Clin Cancer Res; 2021 Mar; 27(5):1491-1504. PubMed ID: 33262138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
    Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
    PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma.
    Yang X; Daifallah AEM; Shankar S; Beer J; Marshall C; Dentchev T; Seykora F; D'Armas S; Hahn J; Lee V; Sabry HH; Farag AM; Seykora JT
    Exp Dermatol; 2019 May; 28(5):609-613. PubMed ID: 30762245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration.
    Farsam V; Basu A; Gatzka M; Treiber N; Schneider LA; Mulaw MA; Lucas T; Kochanek S; Dummer R; Levesque MP; Wlaschek M; Scharffetter-Kochanek K
    Oncotarget; 2016 Dec; 7(50):83554-83569. PubMed ID: 27907906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of miR-148a in cutaneous squamous cell carcinoma by repression of MAPK pathway.
    Luo Q; Li W; Zhao T; Tian X; Liu Y; Zhang X
    Arch Biochem Biophys; 2015 Oct; 583():47-54. PubMed ID: 26253263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Noncoding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity.
    Piipponen M; Nissinen L; Farshchian M; Riihilä P; Kivisaari A; Kallajoki M; Peltonen J; Peltonen S; Kähäri VM
    J Invest Dermatol; 2016 Aug; 136(8):1701-1710. PubMed ID: 27049681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Fargnoli MC; Forsea AM; Frenard C; Harwood CΑ; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
    Eur J Cancer; 2020 Mar; 128():60-82. PubMed ID: 32113941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines.
    Chen IP; Bender M; Spassova I; Henning S; Kubat L; Fan K; Degenhardt S; Mhamdi-Ghodbani M; Sriram A; Volkmer B; Boukamp P; Becker JC; Greinert R
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3215-3231. PubMed ID: 32865618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways.
    Huang Y; Wang Y; Wang Y; Wang N; Duan Q; Wang S; Liu M; Bilal MA; Zheng Y
    J Invest Dermatol; 2022 Feb; 142(2):303-313.e9. PubMed ID: 34358528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GDC-0084 inhibits cutaneous squamous cell carcinoma cell growth.
    Ding LT; Zhao P; Yang ML; Lv GZ; Zhao TL
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1941-1948. PubMed ID: 30072096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.
    Farshchian M; Nissinen L; Siljamäki E; Riihilä P; Piipponen M; Kivisaari A; Kallajoki M; Grénman R; Peltonen J; Peltonen S; Quint KD; Bavinck JNB; Kähäri VM
    Oncotarget; 2017 Jul; 8(28):45825-45836. PubMed ID: 28526809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
    Oberholzer PA; Kee D; Dziunycz P; Sucker A; Kamsukom N; Jones R; Roden C; Chalk CJ; Ardlie K; Palescandolo E; Piris A; MacConaill LE; Robert C; Hofbauer GF; McArthur GA; Schadendorf D; Garraway LA
    J Clin Oncol; 2012 Jan; 30(3):316-21. PubMed ID: 22067401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion.
    Xu N; Zhang L; Meisgen F; Harada M; Heilborn J; Homey B; Grandér D; Ståhle M; Sonkoly E; Pivarcsi A
    J Biol Chem; 2012 Aug; 287(35):29899-908. PubMed ID: 22782903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.
    Escuin-Ordinas H; Li S; Xie MW; Sun L; Hugo W; Huang RR; Jiao J; de-Faria FM; Realegeno S; Krystofinski P; Azhdam A; Komenan SM; Atefi M; Comin-Anduix B; Pellegrini M; Cochran AJ; Modlin RL; Herschman HR; Lo RS; McBride WH; Segura T; Ribas A
    Nat Commun; 2016 Aug; 7():12348. PubMed ID: 27476449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.